Faculty Opinions recommendation of PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718333626.793500614 ◽

2014 ◽

Author(s):

Sebastian Stintzing

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Exon 2 ◽

Multicenter Phase ◽

Download Full-text

Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3109-4 ◽

2016 ◽

Vol 78 (3) ◽

pp. 585-593 ◽

Author(s):

Takao Takahashi ◽

◽

Yasunori Emi ◽

Eiji Oki ◽

Kazuma Kobayashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Exon 2 ◽

Multicenter Phase ◽

Previously Treated ◽

Download Full-text

A Phase II Study of Panitumumab Plus Irinotecan for Metastatic Colorectal Cancer Patients with Wild KRAS Exon 2, Resistant to Fluoropyrimidine, Oxaliplatin and Irinotecan in Japanese. (OGSG1001)

Annals of Oncology ◽

10.1093/annonc/mdu165.235 ◽

2014 ◽

Vol 25 ◽

pp. ii89

Author(s):

Hata Taishi ◽

Yoshida Motoki ◽

Taira Koichi ◽

Sugimoto Naotoshi ◽

Tokunaga Yukihiko ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Exon 2 ◽

Colorectal Cancer Patients ◽

Download Full-text

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

10.1186/s12885-015-1685-z ◽

2015 ◽

Vol 15 (1) ◽

Author(s):

Hitoshi Soda ◽

Hiromichi Maeda ◽

Junichi Hasegawa ◽

Takao Takahashi ◽

Shoichi Hazama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line Therapy ◽

Multicenter Phase ◽

Download Full-text

A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial)

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2017.10.004 ◽

2018 ◽

Vol 17 (1) ◽

pp. e83-e89 ◽

Author(s):

Kohei Akiyoshi ◽

Tetsuya Hamaguchi ◽

Kenichi Yoshimura ◽

Naoki Takahashi ◽

Yoshitaka Honma ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Multicenter Phase ◽

Download Full-text

A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e14563 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e14563-e14563

Author(s):

Dimitrios G. Pectasides ◽

Vasilios Karavasilis ◽

Vassiliki Kotoula ◽

Epaminontas Samantas ◽

Zoi Alexopoulou ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Multicenter Phase ◽

Colorectal Cancer Patients

Download Full-text

A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.3567 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 3567-3567 ◽

Author(s):

Kohei Shitara ◽

Kimio Yonesaka ◽

Tadamichi Denda ◽

Kentaro Yamazaki ◽

Toshikazu Moriwaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Liquid Biopsy ◽

Phase Ii Study ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Exon 2 ◽

Multicenter Phase ◽

Biomarker Analysis ◽

Download Full-text

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2014.12.009 ◽

2015 ◽

Vol 14 (2) ◽

pp. 72-80 ◽

Author(s):

J. Randolph Hecht ◽

Allen Cohn ◽

Shaker Dakhil ◽

Mansoor Saleh ◽

Bilal Piperdi ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Multicenter Phase

Download Full-text

420P A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.941 ◽

2021 ◽

Vol 32 ◽

pp. S545

Author(s):

K. Ding ◽

Y. Liu ◽

J. Du ◽

Y. Zhu ◽

D. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Wild Type ◽

Multicenter Phase ◽

First Line Treatment ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Annals of Oncology ◽

10.1093/annonc/mdx393.004 ◽

2017 ◽

Vol 28 ◽

pp. v159-v160 ◽

Author(s):

J. Bennouna ◽

S. Hiret ◽

C. Borg ◽

A. Bertaut ◽

O. Bouche ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Final Analysis ◽

Wild Type ◽

Multicenter Phase

Download Full-text

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

European Journal of Cancer ◽

10.1016/s0959-8049(01)81497-0 ◽

2001 ◽

Vol 37 ◽

pp. S272 ◽

Author(s):

C. Twelves ◽

C. Butts ◽

J. Cassidy ◽

Th. Conroy ◽

F. DeBraud ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Preliminary Results ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

International Multicenter

Download Full-text